Digoxin (Digoxin) Patent Expiration, LOE Window & CMS Spending
Digoxin (Digoxin) by Hikma Pharmaceuticals: Off-Patent Genericized (AB Competition), 5 AB generics, $40.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Hikma Pharmaceuticals |
| FDA Application & Pathway | N021648 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $40.7M |
| 2024 Medicare Part D Spend | $36.9M |
| 2024 Medicaid Spend | $3.8M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 20.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.